The 34th iteration of the Drug Delivery to the Lungs (DDL) Conference, DDL 2023, drew approximately 930 OINDP specialists to the Edinburgh International Conference Centre (EICC) December 6 - 8, with more than 100 additional attendees joining online. The conference also drew support from 115 sponsors, including almost 20 new companies exhibiting for the first time. … [Read more...] about DDL 2023 highlighted novel technologies
Features
Previewing DDL 2023
The annual Drug Delivery to the Lungs meeting returns to the Edinburgh International Conference Centre (EICC) December 6-8. DDL 2022 attracted a total of more than 1,000 delegates in person and online, and DDL 2023 is also expected to draw a large crowd, says organizing committee member Michelle Dawson. For the first time, DDL will take over the entire EICC, providing … [Read more...] about Previewing DDL 2023
ISAM Congress 2023
The International Society for Aerosols in Medicine (ISAM) welcomed more than 260 attendees to its 2023 biannual congress August 26-30 in Saarbrücken, Germany, reports organizing committee member Claus-Michael Lehr of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). In addition to the scientific program, the meeting included 6 workshops, 21 … [Read more...] about ISAM Congress 2023
Q&A with Intertek’s Chris Vernall on in-vitro only BE and the new nasal bioequivalence guidances
Intertek Pharmaceutical Services Commercial Director Chris Vernall on how the new FDA nasal bioequivalence guidances support an in vitro only bioequivalence pathway and continue wider industry focus on evolving analytical and in silico tools for generic OINDP testing What is the main difference in in-vitro bioequivalence (IVBE) recommendations between the May 2023 … [Read more...] about Q&A with Intertek’s Chris Vernall on in-vitro only BE and the new nasal bioequivalence guidances
Aerosol School goes virtual for 2023
After pausing for several years due to the COVID-19 pandemic, the 2023 edition of Aerosol School will take place virtually. Students will have access to more than 200 hours of lectures from well-known experts on topics ranging from the basics of aerosol delivery devices to hot topics such as the delivery of macrophages and monoclonal antibodies via inhalation. … [Read more...] about Aerosol School goes virtual for 2023
RDD Europe 2023 highlighted sustainability, nasal drug delivery, and biologics
At RDD Europe 2023, which took place May 2-5 in Antibes, France, Richard Dalby noted in his opening remarks that approximately 420 inhaled and nasal drug delivery experts from 28 countries were attending the conference in person with another 20 or so delegates attending virtually. Noting that 2023 was the first in-person version of RDD Europe since 2019, he welcomed … [Read more...] about RDD Europe 2023 highlighted sustainability, nasal drug delivery, and biologics
In Memoriam: Charles G. Thiel
Charles G. Thiel, one of the most influential scientists working in respiratory drug delivery over the past 7 decades, passed away on March 10, 2023 at the age of 94. In 1956, Thiel and co-workers at Riker Laboratories developed the first pressurized metered dose inhaler for delivery of medication to the lungs. Following the 1970 acquisition of Riker by 3M (now … [Read more...] about In Memoriam: Charles G. Thiel
RDD Europe 2023 returns to Antibes
RDD Europe 2023, organized by RDD Online and Aptar Pharma, returns to Antibes, France, May 2-5 at the Palais des Congrès Antipolis. Richard Dalby of RDD Online says that conference center (previously called the Palais des Congrès Antibes) proved popular with attendees at RDD Europe 2015 and 2017, which took place at the same venue. Dalby expects that attendance will … [Read more...] about RDD Europe 2023 returns to Antibes
DDL 2022 looked to the future of OINDP development
In its return to the Edinburgh International Conference Centre after two years of online-only meetings, the Drug Delivery to the Lungs conference looked toward the future, focusing on scientific and technical innovations that will influence inhaled and nasal drug development for years to come. The meeting drew a record crowd, with approximately 130 virtual … [Read more...] about DDL 2022 looked to the future of OINDP development
Q&A with Mark Copley: Reducing Inhaler Testing Variability Through Test Environment Control
Copley Scientific CEO Mark Copley answers questions about the importance of the test environment for OIP testing Why is the test environment so important for inhaler testing? Due to a broad range of factors, including interaction between formulation, device, and patient, orally inhaled product (OIP) testing is naturally more variable than testing for simple … [Read more...] about Q&A with Mark Copley: Reducing Inhaler Testing Variability Through Test Environment Control